Jeffrey M Leiden bought $100k of ODTX
director at Odyssey Therapeutics, Inc.. 5,000 shares at an average of $20.00, traded May 8, 2026, filed May 11, 2026.
Score components
- +15RoleDirector
- +10Trade size$100k at market
- 0Relative to holdingsHoldings up 1.9%
- 0Price contextNo price history yet
- +15Cluster7 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.2%, 3m +27.0%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-217607, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 8, 2026 | POpen-market purchase Common Stock | +5,000 | $20.00 | $100k | 270,198 | May 11, 2026 |
| May 11, 2026 | CConversion Common Stockindirect: See footnote | +28,698 | - | - | 28,698 | May 11, 2026 |
| May 11, 2026 | MOption exercise Common Stockindirect: See footnote | +2,963 | - | - | 31,661 | May 11, 2026 |
| May 11, 2026 | FTax withholding Common Stockindirect: See footnote | -17 | $18.00 | $306 | 31,644 | May 11, 2026 |
| May 11, 2026 | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -79,166 | - | - | 0 | May 11, 2026 |
| May 11, 2026 | CConversion Series C Convertible Preferred Stockderivativeindirect: See footnote | -100,000 | - | - | 0 | May 11, 2026 |
| May 11, 2026 | CConversion Series D Convertible Preferred Stockderivativeindirect: See footnote | -96,002 | - | - | 0 | May 11, 2026 |
| May 7, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +626,220 | $0.00 | $0 | 626,220 | May 11, 2026 |
| May 11, 2026 | MOption exercise Series D Warrants (Right to Buy)derivativeindirect: See footnote | -28,800 | - | - | 0 | May 11, 2026 |
Related signals
Other insiders at Odyssey Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 58Moderate | Odyssey Therapeutics, Inc. | Tpg Gp A, LLC other | $25M 1,388,889 shares | +60% | |
| 61Notable | Odyssey Therapeutics, Inc. | Dimension Capital II, L.P. director | $20M 1,111,111 shares | +50% | |
| 50Moderate | Odyssey Therapeutics, Inc. | Shelley Chu director | $200k 11,111 shares | - | |
| 53Moderate | Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC owner | $10.0M 555,555 shares | +35% | |
| 17Weak | ODTXsell Odyssey Therapeutics, Inc. | Sr One Capital Management, LLC owner | $32k 1,780 shares | -0% | |
| 37Weak | Odyssey Therapeutics, Inc. | Jason Haas Chief Financial Officer | $20k 1,000 shares | +2% | |
| 61Notable | Odyssey Therapeutics, Inc. | Nan (LN) Li director | $20M 1,111,111 shares | +50% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.